Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.

Anton M Sholukh,Jennifer D Watkins,Hemant K Vyas,Sandeep Gupta,Samir K Lakhashe,Swati Thorat,Mingkui Zhou,Girish Hemashettar,Barbara C Bachler,Donald N Forthal,Francois Villinger,Quentin J Sattentau,Robin A Weiss,Gloria Agatic,Davide Corti,Antonio Lanzavecchia,Jonathan L Heeney,Ruth M Ruprecht

Vaccine（2015）

引用 61|浏览33

暂无评分

摘要

•We used IgG1 and dimeric IgA2 versions of the V3-loop specific mAb HGN194.•HGN194 IgG1 given iv at a low dose to monkeys: 0% protection from SHIV infection.•Same iv HGN194 IgG1 dose plus mucosally administered dimeric IgA2: 100% protection.•HGN194 dimeric IgA2 given mucosally as single agent: only 17% protection.•Systemic plus mucosal passive immunization: proof-of-concept for defense-in-depth.

查看译文

关键词

Ab,mAb,nmAb,ADCC,AID50,C1,CTL,dIgA,Env,FcγR,FcRn,PBS,HIV-C,IC50,IC90,Ig,i.r.,i.v.,RM,SHIV,TCID50,V1V2,vRNA

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要